NeOnc Technologies Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
31.1%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.85next fiscal year
Monitoring Framework
Key Performance Indicators
NEO100 Phase 2a Clinical Trial Enrollment Status Quarterly100.0Target: Fully Enrolled
NEO100 Radiographic Remission Rate Annually2,400.0%Target: Significantly exceed historical salvage therapy benchmark of ~8%
NEO100 Six-Month Progression-Free Survival (PFS) Rate Annually4,400.0%Target: Exceed historical benchmarks of 21-31%
NEO212 Recommended Phase 2 Dose (RP2D) Quarterly610.0Target: 610 mg
Watch Items
- NEO100 Phase 2a Preliminary Data ReadoutTrigger: Expected around August 2026 (approximately 5 months from April 2026 update)Action: Evaluate efficacy endpoints (radiographic remission, PFS, overall survival) to validate intranasal delivery platform.
- NEO212 Type B End-of-Phase 1 FDA MeetingTrigger: Scheduling and alignment on registrational Phase 2 study designAction: Align with FDA on potential pivotal registrational Phase 2 study and explore Accelerated Approval pathways.
- Cash Runway and Liquidity ManagementTrigger: Cash reserves expected to support operations into September 2026Action: Secure additional capital, PIPE financing, or strategic partnerships to extend the operational runway beyond Q3 2026.
Research as of 20 Jun 2026